Annual Revenue ($)

Osmotica Pharmaceuticals revenue was $240.03 m in FY, 2019

Quarterly Revenue ($)

FY, 2016FY, 2017FY, 2018FY, 2019
Revenue$170.52 m$237.67 m$263.7 m$240.03 m
Q3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020
Revenue$53.74 m$66.34 m$57.13 m$57.53 m$65.46 m$48.65 m$37.53 m

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Osmotica Pharmaceuticals revenue breakdown by business segment: 9.4% from Lorzone, 7.8% from Divigel, 40.4% from Venlafaxine ER, 18.4% from Methylphenidate and 24.0% from Other

FY, 2017FY, 2016
Lorzone$22.28 m$29 m
Divigel$18.54 m$15.85 m
Venlafaxine ER$96.05 m$25.57 m
OB Complete$10.45 m$12.76 m
Other$46.64 m$87.34 m
Methylphenidate$43.71 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu